ArticleFrontiers in psychiatry2026
The role of metacognitive beliefs in impulse control disorders and addictive-like behaviors in Parkinson's disease: an exploratory study.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Impulse control disorders (ICDs) are clinically relevant non-motor complications of Parkinson's disease (PD). ICDs include gambling, hypersexuality, compulsive shopping, binge eating, hobbyism/punding, and dopamine dysregulation syndrome. Although dopaminergic replacement therapies are a key risk factor, only a subgroup of treated patients develop ICDs, potentially suggesting that neuropsychological differences may contribute to interindividual variability. Dysfunctional Metacognitive Beliefs (MBs) have recently been associated with addictive behaviors in the general population, but their role in neurologically driven addictive-like behaviors has not yet been examined. This exploratory study aimed to investigate whether dysfunctional MBs are associated with ICD symptom severity in PD patients after controlling for variables of dopaminergic exposure. Methods: 38 PD patients (44.7% F, mean age 67.55) completed the Metacognitions Questionnaire-30 (MCQ-30) and the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS). One-sample t-tests were used to compare MCQ scores with normative values from the Italian general community sample. Two-tailed partial correlations tested associations between MCQ-30 scores and QUIP-RS outcomes, controlling for treatment duration, dopamine agonist exposure (LEDD-DA), and other dopaminergic exposures (i.e., total LEDD minus LEDD-DA). Additionally, independent samples t-tests were conducted to compare MCQ-30 scores between patients with and without ICDs. False discovery rate correction was applied. Results: Overall, 23.7% of patients exceeded the QUIP-ICD cut-off. Compared with normative data from the general community sample, PD patients showed a more dysfunctional metacognitive profile. After controlling for dopaminergic exposure, ICD symptom severity was associated with positive beliefs about worry, negative beliefs about uncontrollability and danger, reduced cognitive confidence, greater need to control thoughts, and lower cognitive self-consciousness. In group comparisons, patients exceeding the QUIP-ICD cut-off showed significantly higher MCQ-POS, MCQ-NEG, and MCQ-NC scores and lower MCQ-CSC scores than those below the cut-off. Discussion: These exploratory findings suggest that, after controlling for dopaminergic variables, dysfunctional MBs are associated with ICD symptom severity. In this context, MBs may represent one of the cognitive-affective correlates of ICD interindividual variability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.